Galactomannan and the diagnosis of invasive aspergillosis

Clinical Infectious Diseases

Volumn 42, Issue 10, 2006, Pages 1428-1430

  Rex, John H ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGUS ANTIGEN; GALACTOMANNAN;

ANTIMICROBIAL THERAPY; ASPERGILLOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; HEMATOLOGIC MALIGNANCY; HUMAN; LABORATORY DIAGNOSIS; NOTE; ORGAN TRANSPLANTATION; PERFORMANCE; PRIORITY JOURNAL; REPEAT PROCEDURE; TIME;

ASPERGILLOSIS; HUMANS; MANNANS; REPRODUCIBILITY OF RESULTS;

EID: 33646447339     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/503432     Document Type: Note

References (14)

1. Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002; 15:465-84.
2. Pickering JW, Sant HW, Bowles CAP, Roberts WL, Woods GL. Evaluation of a (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43:5957-62.
3. Verweij PE. Advances in diagnostic testing. Med Mycol 2005; 43:5121-4.
4. Kappe R, Schulze-Berge A. New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test. J Clin Microbiol 1993; 31:2489-90.
5. Rimek D, Zimmermann T, Hartmann M, Prariyachatigul C, Kappe R. Disseminated Penicillium marneffei infection in an HIV-positive female from Thailand in Germany. Mycoses 1999; 42:25-8.
6. Pfeiffer C, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-27 (in this issue).
7. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
8. Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005;41:S381-6.
9. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762-9.
10. International Conference on Harmonisation. Statistical principles for clinical trials. CPMP/ICH/363/96. London: European Agency for the Evaluation of Medicinal Products, 1998. Available at: http://www.emea.eu.int/pdfs/human/ich/ 036396en.pdf. Accessed 8 February 2006.
11. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46:12-23.
12. Odabasi Z, Mattiuzzi G, Estey E, et al. β-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199-205.
13. White PL, Archer AE, Barnes RA. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol 2005; 43:2181-7.
14. Aubry A, Porcher R, Bottero J, et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006; 44:389-94.